glaucomaНациональный журнал ГлаукомаNational Journal glaucoma2078-41042311-6862Federal State Budgetary Institution of Science “Krasnov Research Institute of Eye Diseases”10.25700/NJG.2019.03.02glaucoma-254Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESКомплексная оценка применения латанопроста в клинической практике: медико-статистическое наблюдениеComplex assessment of Latanoprost use in clinical practice: the results of a questionnaire surveyЛоскутовИ. А.LoskoutovI. A.

д.м.н., заведующий офтальмологическим отделением

123567,   Москва, Волоколамское шоссе, 84

 Med.Sc.D., Professor, Head of Ophthalmology Dept

84 Volokolamsk highway, Moscow, 123567

КорнееваА. В.KorneevaA. V.

 к.м.н., врач-офтальмолог

129301,  Москва, ул. Бориса Галушкина, 3

Ph.D., Ophthalmologist

3 Borisa Galushkina Str., Moscow, 129301

a-bel@mail.ruОфтальмологическое отделение Научно-практического центра ОАО «РЖД»РоссияScience clinical center Russian railways (Ophthalmology Department)Russian Federation2ООО «Три-З-МСК»РоссияLLC «Tri-Z-MSK»Russian Federation2019141220191832028Copyright © Лоскутов И.А., Корнеева А.В., 20192019Лоскутов И.А., Корнеева А.В.Loskoutov I.A., Korneeva A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.glaucomajournal.ru/jour/article/view/254

Первичная открытоугольная глаукома — это хроническое заболевание, которое нередко требует пожизненного лечения. Соблюдение пациентом режима лечения, приверженность и постоянство терапии играют жизненно важную роль в улучшении результатов за счет снижения заболеваемости и экономических последствий, связанных с прогрессированием заболевания.

ЦЕЛЬ

ЦЕЛЬ. Оценка места препарата Ксалатан в современной консервативной медикаментозной терапии глаукомного процесса.

МЕТОДЫ

МЕТОДЫ. Неклиническое эпидемиологическое одномоментное исследование выполнялось путем анкетирования 231 врача-офтальмолога амбулаторно-поликлинического звена в 19 городах Российской Федерации на оценку удовлетворённости применением препарата Ксалатан в их клинической практике в зависимости от региона практики и стажа врача.

РЕЗУЛЬТАТЫ

РЕЗУЛЬТАТЫ. В результате анализа данных сделаны выводы о том, что на данный момент оригинальный препарат Ксалатан занимает как минимум одно из ведущих мест в структуре назначений препаратов простагландинового ряда врачами-офтальмологами на территории РФ.

ЗАКЛЮЧЕНИЕ

ЗАКЛЮЧЕНИЕ. После проведенной оценки количества случаев недостаточной эффективности препарата Ксалатан можно сделать вывод о высокой степени удовлетворенности врачей результатами лечения. При этом частота назначения Ксалатана препаратом первого выбора, второго выбора, общий процент больных, получающих Ксалатан, и количество пациентов, которым пришлось отменить Ксалатан в связи с недостаточной эффективностью, не зависели от опыта работы врача, что свидетельствует о высокой информированности врачей о Ксалатане.

Primary open-angle glaucoma is a chronic optic neuropathy, which often requires a lifelong treatment. Patient compliance, adherence to therapy and persistence play a vital role in improving the outcomes by reducing morbidity and the economic consequences that are associated with disease progression.

PURPOSE

PURPOSE: To assess the role of Xalatan use in modern conservative drug therapy of glaucoma process.

METHODS

METHODS: A non-clinical, epidemiological, single-step study was conducted by interviewing 231 outpatient ophthalmologists in 19 cities of the Russian Federation. RESULTS: Data analysis allowed us to conclude that Xalatan presently is one of the leading prostaglandin ana logues prescribed by ophthalmologists on the territory of the Russian Federation.

CONCLUSION

CONCLUSION: After assessing the number of cases of insufficient Xalatan efficacy, we could conclude that doctors are highly satisfied with the treatment results. At the same time, the frequency of choosing Xalatan as the first line drug, second line drug, as well as total percentage of patients receiving Xalatan, and the number of patients who had to cancel Xalatan due to lack of effectiveness did not depend on the doctor’s experience, which indicates that doctors were highly aware of Xalatan.

первичная открытоугольная глаукомааналоги простагландиновлатанопростprimary open-angle glaucomaprostaglandin analogueslatanoprostReferencesResnikoff S., Pascolini D., Etya’ale D., Kocur I. et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004; 82(11):844–851. doi:S0042-96862004001100009Resnikoff S., Pascolini D., Etya’ale D., Kocur I. et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004; 82(11):844–851. doi:S0042-96862004001100009Quigley H.A., Broman A.T. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006; 90(3):262-267. doi: 10.1136/bjo.2005.081224Quigley H.A., Broman A.T. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006; 90(3):262-267. doi: 10.1136/bjo.2005.081224Heijl A., Bengtsson B., Chauhan B.C., Lieberman M.F. et al. A comparison of visual field progression criteria of 3 major glaucoma trials in early manifest glaucoma trial patients. Ophthalmology. 2008; 115:1557–1565. doi:10.1016/j. ophtha.2008.02.005Heijl A., Bengtsson B., Chauhan B.C., Lieberman M.F. et al. A comparison of visual field progression criteria of 3 major glaucoma trials in early manifest glaucoma trial patients. Ophthalmology. 2008; 115:1557–1565. doi:10.1016/j. ophtha.2008.02.005Gillespie B.W., Musch D.C., Guire K.E., Mills R.P. et al. CIGTS (Collaborative Initial Glaucoma Treatment Study) Study Group. The collaborative initial glaucoma treatment study: Baseline visual field and test-retest variability. Invest Ophthalmol Vis Sci. 2003; 44:2613–2620. doi:10.1167/iovs.02-0543Gillespie B.W., Musch D.C., Guire K.E., Mills R.P. et al. CIGTS (Collaborative Initial Glaucoma Treatment Study) Study Group. The collaborative initial glaucoma treatment study: Baseline visual field and test-retest variability. Invest Ophthalmol Vis Sci. 2003; 44:2613–2620. doi:10.1167/iovs.02-0543Ernest P.J., Schouten J.S., Beckers H.J., Hendrikse F. et al. An evidence-based review of prognostic factors for glaucomatous visual field progression. Ophthalmology. 2013; 120:512–519. doi:10.1016/j.ophtha.2012.09.005Ernest P.J., Schouten J.S., Beckers H.J., Hendrikse F. et al. An evidence-based review of prognostic factors for glaucomatous visual field progression. Ophthalmology. 2013; 120:512–519. doi:10.1016/j.ophtha.2012.09.005Bagnis A., Papadia M., Scotto R., Traverso C.E. Current and emerging medical therapies in the treatment of glaucoma. Expert Opin Emerg Drugs. 2011; 16(2):293–307. doi: 10.1517/14728214.2011.563733Bagnis A., Papadia M., Scotto R., Traverso C.E. Current and emerging medical therapies in the treatment of glaucoma. Expert Opin Emerg Drugs. 2011; 16(2):293–307. doi: 10.1517/14728214.2011.563733Curran M.P., Orman J.S. Bimatoprost/timolol: a review of its use in glaucoma and ocular hypertension. Drugs Aging. 2009; 26(2): 169–184. doi: 10.2165/0002512-200926020-00008Curran M.P., Orman J.S. Bimatoprost/timolol: a review of its use in glaucoma and ocular hypertension. Drugs Aging. 2009; 26(2): 169–184. doi: 10.2165/0002512-200926020-00008Chauhan B.C., Mikelberg F.S., Balaszi A.G. et al. Canadian glaucoma study: risk factors for the progression of open-angle glaucoma. Arch Ophthalmol. 2008; 126(8):1030–1036. doi: 10.1001/archopht.126.8.1030Chauhan B.C., Mikelberg F.S., Balaszi A.G. et al. Canadian glaucoma study: risk factors for the progression of open-angle glaucoma. Arch Ophthalmol. 2008; 126(8):1030–1036. doi: 10.1001/archopht.126.8.1030Heijl A., Leske M.C., Bengtsson B. et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 2002; 120(10):1268–1279.Heijl A., Leske M.C., Bengtsson B. et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 2002; 120(10):1268–1279.Garway-Heath D.F., Crabb D.P., Bunce C., Lascaratos G. et al. Latanoprost for open-angle glaucoma (UKGTS): A randomised, multicentre, placebo-controlled trial. Lancet. 2015; 385:1295–1304. doi:10.1016/ S0140-6736(14)62111-5Garway-Heath D.F., Crabb D.P., Bunce C., Lascaratos G. et al. Latanoprost for open-angle glaucoma (UKGTS): A randomised, multicentre, placebo-controlled trial. Lancet. 2015; 385:1295–1304. doi:10.1016/ S0140-6736(14)62111-5van der Valk R., Webers C.A., Schouten J.S., Zeegers M.P. et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: A meta-analysis of randomized clinical trials. Ophthalmology. 2005; 112:1177–1185.van der Valk R., Webers C.A., Schouten J.S., Zeegers M.P. et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: A meta-analysis of randomized clinical trials. Ophthalmology. 2005; 112:1177–1185.European Glaucoma Society. Terminology and Guidelines for Glaucoma. 4th ed. Savona, Italy: PubliComm; 2014. doi:10.1136/bjophthalmol-2016-egsguideline.001European Glaucoma Society. Terminology and Guidelines for Glaucoma. 4th ed. Savona, Italy: PubliComm; 2014. doi:10.1136/bjophthalmol-2016-egsguideline.001Stjernschantz J., Resul B. Phenyl substituted prostaglandin analogsfor glaucoma treatment. Drugs Future. 1992; 17:691-704. doi:10.1358/ dof.1992.017.08.187766Stjernschantz J., Resul B. Phenyl substituted prostaglandin analogsfor glaucoma treatment. Drugs Future. 1992; 17:691-704. doi:10.1358/ dof.1992.017.08.187766Aung T., Chan Y.H., Chew P.T. EXACT Study Group. Degree of angle closure and the intraocular pressure-lowering effect of latanoprost in subjects with chronic angle-closure glaucoma. Ophthalmology. 2005; 112:267–271. doi:10.1016/j.ophtha.2004.08.024.Aung T., Chan Y.H., Chew P.T. EXACT Study Group. Degree of angle closure and the intraocular pressure-lowering effect of latanoprost in subjects with chronic angle-closure glaucoma. Ophthalmology. 2005; 112:267–271. doi:10.1016/j.ophtha.2004.08.024.Boland M.V., Ervin A.M., Friedman D.S., Jampel H.D. et al. Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013; 158:271-279. doi:10.7326/0003-4819-158-4-20130219000008Boland M.V., Ervin A.M., Friedman D.S., Jampel H.D. et al. Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013; 158:271-279. doi:10.7326/0003-4819-158-4-20130219000008Lin L., Zhao Y.J., Chew P.T., Sng C.C. et al. Comparative efficacy and tolerability of topical prostaglandin analogues for primary openangle glaucoma and ocular hypertension. Ann Pharmacother. 2014; 48(12):1585-1593. doi:10.1177/1060028014548569Lin L., Zhao Y.J., Chew P.T., Sng C.C. et al. Comparative efficacy and tolerability of topical prostaglandin analogues for primary openangle glaucoma and ocular hypertension. Ann Pharmacother. 2014; 48(12):1585-1593. doi:10.1177/1060028014548569Cucherat M., Stalmans I., Rouland J.F. Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of openangle glaucoma and ocular hypertension: an adjusted in direct comparison meta-analysis of randomized clinical trials. J Glaucoma. 2014; 23:69-75. doi:10.1097/IJG.0b013e3182a075e6Cucherat M., Stalmans I., Rouland J.F. Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of openangle glaucoma and ocular hypertension: an adjusted in direct comparison meta-analysis of randomized clinical trials. J Glaucoma. 2014; 23:69-75. doi:10.1097/IJG.0b013e3182a075e6Eyawo O., Nachega J., Lefebvre P., Meyer D. et al. Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis. Clin Ophthalmol. 2009; 3:447-456. doi:10.2147/opth.s6501Eyawo O., Nachega J., Lefebvre P., Meyer D. et al. Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis. Clin Ophthalmol. 2009; 3:447-456. doi:10.2147/opth.s6501Honrubia F., Garcia-Sánchez J., Polo V., Martinez J.M. et al. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. Br J Ophthalmol. 2009; 93:316-321. doi:10.1136/bjo.2007.135111Honrubia F., Garcia-Sánchez J., Polo V., Martinez J.M. et al. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. Br J Ophthalmol. 2009; 93:316-321. doi:10.1136/bjo.2007.135111Orme M., Collins S., Dakin H., Kelly S. et al. Mixed treatment comparison and meta-regression of the efficacy and safety of prostaglandin analogues and comparators for primary open-angle glaucoma and ocular hypertension. Curr Med Res Opin. 2010; 26:511-528. doi:10.1185/03007990903498786Orme M., Collins S., Dakin H., Kelly S. et al. Mixed treatment comparison and meta-regression of the efficacy and safety of prostaglandin analogues and comparators for primary open-angle glaucoma and ocular hypertension. Curr Med Res Opin. 2010; 26:511-528. doi:10.1185/03007990903498786Kara C., Şen E.M., Elgin K.U., Serdar K. et al. Does the intraocular pressurelowering effect of prostaglandin analogues continue over the long term? Int Ophthalmology. 2017; 37(3):619-626. doi:10.1007/ s10792-016-0315-3Kara C., Şen E.M., Elgin K.U., Serdar K. et al. Does the intraocular pressurelowering effect of prostaglandin analogues continue over the long term? Int Ophthalmology. 2017; 37(3):619-626. doi:10.1007/ s10792-016-0315-3Национальное руководство по глаукоме: для практикующих врачей /под ред. Е.А. Егорова, Ю.С. Астахова, В.П. Еричева. М.: ГЭОТАР-Медиа; 2015: 190–197. http://www.glaucomanews.ru/files/glaukoma_wm.pdfNational Guide to Glaucoma: for Practitioners. Ed by E.A. Egorov, Yu.S. Astakhov, V.P. Erichev. Moscow: GEOTAR-Media; 2015: 190-197. (In Russ.). http://www.glaucomanews.ru/files/glaukoma_wm.pdfAmerican Academy of Ophthalmology Glaucoma Panel. Primary open-angle glaucoma suspect. San Francisco (CA): American Academy of Ophthalmology; 2010.American Academy of Ophthalmology Glaucoma Panel. Primary open-angle glaucoma suspect. San Francisco (CA): American Academy of Ophthalmology; 2010.Connor A.J., Fraser S.G. Glaucoma prescribing trends in England 2000 to 2012. Eye (Lond). 2014; 28:863-869. doi:10.1038/ eye.2014.114Connor A.J., Fraser S.G. Glaucoma prescribing trends in England 2000 to 2012. Eye (Lond). 2014; 28:863-869. doi:10.1038/ eye.2014.114Schmier J.K., Lau E.C., Covert D.W. Two-year treatment patterns and costs in glaucoma patients initiating treatment with prostaglandin analogs. Clin Ophthalmol. 2010; 4:1137-1143. doi:10.2147/OPTH. S13884Schmier J.K., Lau E.C., Covert D.W. Two-year treatment patterns and costs in glaucoma patients initiating treatment with prostaglandin analogs. Clin Ophthalmol. 2010; 4:1137-1143. doi:10.2147/OPTH. S13884Daka Q., Trkulja V. Efficacy and tolerability of mono-compound topical treatments for reduction of intraocular pressure in patients with primary open angle glaucoma or ocular hypertension: an overview of reviews. Croat Med J. 2014; 55(5):468-480. doi:10.3325/ cmj.2014.55.468Daka Q., Trkulja V. Efficacy and tolerability of mono-compound topical treatments for reduction of intraocular pressure in patients with primary open angle glaucoma or ocular hypertension: an overview of reviews. Croat Med J. 2014; 55(5):468-480. doi:10.3325/ cmj.2014.55.468WHO web link: http://www.who.int/medicines/publications/essentialmedicines/EML2015_8-May-15.pdf.WHO web link: http://www.who.int/medicines/publications/essentialmedicines/EML2015_8-May-15.pdf.Нероев В.В., Киселева О.А., Бессмертный А.М. Основные результаты мультицентрового исследования эпидемиологических особенностей первичной открытоугольной глаукомы в Российской Федерации. Российский офтальмологический журнал. 2013; 6(3):43–46.Neroev V.V., Kiseleva O.A., Bessmertnyj A.M. The main results of a multicenter study of epidemiological features of primary open-angle glaucoma in the Russian Federation. Rossijskij oftal’mologicheskij zhurnal. 2013; 6(3):43–46. (In Russ.).

The authors declare that there are no conflicts of interest present.